Want to see HK:2137 full AI Analyst Report?

Brii Biosciences Limited (2137) Price & Analysis

3 Followers

2137 Stock Chart & Stats

HK$1.44

HK$0.04(3.74%)

At close: Jan 09 4:00 PM EST

HK$1.44

HK$0.04(3.74%)

Day’s Range― - ―

52-Week RangeHK$0.84 - HK$2.34

Previous CloseN/A

Volume2.92M

Average Volume (3M)721.75K

Market Cap

HK$639.18M

Enterprise Value-HK$1.40K

Total Cash (Recent Filing)HK$1.77B

Total Debt (Recent Filing)HK$6.18M

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Mar 19, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.24

Shares Outstanding734,958,250

10 Day Avg. Volume538,190

30 Day Avg. Volume721,746

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)0.38

Price to Sales (P/S)50.44

P/FCF Ratio-3.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.43

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Positive EquityVery low leverage and positive equity provide a financial cushion while the company funds development and commercialization. This reduces balance-sheet pressure, preserves borrowing and partnership flexibility, and gives management more room to absorb operating setbacks over the next several quarters.

Improved 2025 Losses And Cash BurnThe reduction in 2025 losses and cash burn indicates some improvement in financial execution compared with the prior year. While not yet sufficient to establish profitability, this progress could support longer-term stabilization if management continues controlling costs and improving operating efficiency.

Partner-enabled Commercialization ModelA partnered, in-licensed model gives Brii access to external drug candidates and commercial capabilities without relying solely on internally originated assets. Such collaborations can share development costs, expand market access, and create potential milestone or royalty income as products advance.

Bears Say

Persistent Losses And Negative MarginsPersistent losses and deeply negative margins show that the business has not yet converted its development and commercialization activities into sustainable earnings. Continued unprofitability can restrict reinvestment capacity, weaken operating resilience, and extend dependence on funding or successful product execution.

Sharp Revenue ContractionA sharp revenue decline undermines evidence of durable commercial scale and suggests that product demand, market coverage, or contribution from partnered assets remains uneven. Unless reversed, weaker revenue reduces operating leverage and makes a path toward sustainable profitability more difficult.

Ongoing Operating And Free Cash BurnConsistently negative operating and free cash flow means the company is not currently self-funding its activities. Ongoing cash consumption can require external financing or use of existing liquidity, limiting strategic flexibility and increasing the importance of successful commercialization and cost discipline.

Brii Biosciences Limited News

Brii Biosciences Narrows Interim Loss as HBV and RNA Pipelines Advance

An announcement from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences Limited reported unaudited interim...

1M ago

Brii Biosciences Sets August Board Meeting to Approve 2026 Interim Results

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an announcement. Brii Biosciences Limited has announced that its board...

1M ago

Brii Biosciences Posts Promising Phase 2b Hepatitis B Data but Elebsiran Future Clouded by Arbitration

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an announcement. Brii Biosciences has reported end-of-treatment data from its...

3M ago

Brii Biosciences Launches HK$60 Million Share Buy-back to Signal Confidence and Unlock Value

Brii Biosciences Limited ( ($HK:2137) ) has provided an announcement. Brii Biosciences Limited has announced that its board...

3M ago

Brii Biosciences Shareholders Approve All Resolutions at 2026 AGM

Brii Biosciences Limited ( ($HK:2137) ) has shared an announcement. Brii Biosciences reported that all resolutions proposed at...

3M ago

Brii Biosciences Warns Hepatitis B Drug Program at Risk Amid Vir Arbitration

Brii Biosciences Limited ( ($HK:2137) ) has provided an update. Brii Biosciences has disclosed that its ongoing arbitration...

4M ago

Brii Biosciences Data Backs Shorter NRTI Use in Next-Generation HBV Therapies

An announcement from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences has presented new data...

5M ago

Brii Biosciences Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority

Brii Biosciences Limited ( ($HK:2137) ) has shared an update. Brii Biosciences Limited has called its annual general...

5M ago

Brii Biosciences Launches Arbitration Against Vir Over Hepatitis B Drug Manufacturing Rights

The latest announcement is out from Brii Biosciences Limited ( ($HK:2137) ). Brii Biosciences has initiated arbitration proceedings...

5M ago

Brii Biosciences Narrows 2025 Loss as Costs Fall and Revenue Emerges

An announcement from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences reported its annual results...

6M ago

2137 FAQ

What was Brii Biosciences Limited’s price range in the past 12 months?

Brii Biosciences Limited lowest stock price was HK$0.83 and its highest was HK$2.34 in the past 12 months.

What is Brii Biosciences Limited’s market cap?

Brii Biosciences Limited’s market cap is HK$639.18M.

When is Brii Biosciences Limited’s upcoming earnings report date?

Brii Biosciences Limited’s upcoming earnings report date is Mar 19, 2027 which is in 179 days.

How were Brii Biosciences Limited’s earnings last quarter?

Brii Biosciences Limited released its earnings results on Aug 20, 2026. The company reported -HK$0.163 earnings per share for the quarter, missing the consensus estimate of -HK$0.128 by -HK$0.035.

Is Brii Biosciences Limited overvalued?

According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brii Biosciences Limited pay dividends?

Brii Biosciences Limited does not currently pay dividends.

What is Brii Biosciences Limited’s EPS estimate?

Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brii Biosciences Limited have?

Brii Biosciences Limited has 734,958,250 shares outstanding.

What happened to Brii Biosciences Limited’s price movement after its last earnings report?

Brii Biosciences Limited reported an EPS of -HK$0.163 in its last earnings report, missing expectations of -HK$0.128. Following the earnings report the stock price went up 3.571%.

Which hedge fund is a major shareholder of Brii Biosciences Limited?

Currently, no hedge funds are holding shares in HK:2137

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brii Biosciences Limited

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.